Actively Recruiting

Age: 18Years +
MALE
NCT07146113

Treatment Approaches and Biomarkers PRevalence In de Novo MEtastatic Hormone-sensitive Prostate Cancer in Russian Federation

Led by AstraZeneca · Updated on 2025-12-23

400

Participants Needed

17

Research Sites

104 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

A multicentre observational study on treatment approaches and biomarkers in de novo metastatic hormone sensitive prostate cancer in Russian Federation

CONDITIONS

Official Title

Treatment Approaches and Biomarkers PRevalence In de Novo MEtastatic Hormone-sensitive Prostate Cancer in Russian Federation

Who Can Participate

Age: 18Years +
MALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Male patients aged  18 years old
  • Signed informed consent form including consent for tumor tissue testing
  • Histologically confirmed high-aggressive metastatic prostate cancer with Gleason score 8-10
  • Diagnosis of metastatic prostate cancer within 2 years prior to inclusion
  • Availability of source medical documentation
  • Presence of biopsy FFPE tumor tissue sample from routine clinical practice
  • Unknown homologous recombination repair mutation status
Not Eligible

You will not qualify if you...

  • Participation in any interventional clinical trial since metastatic prostate cancer diagnosis

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 17 locations

1

Research Site

Arkhangelsk, Russia

Actively Recruiting

2

Research Site

Barnaul, Russia

Actively Recruiting

3

Research Site

Chelyabinsk, Russia

Actively Recruiting

4

Research Site

Irkutsk, Russia

Not Yet Recruiting

5

Research Site

Krasnodar, Russia

Not Yet Recruiting

6

Research Site

Krasnoyarsk, Russia

Actively Recruiting

7

Research Site

Moscow, Russia

Not Yet Recruiting

8

Research Site

Moscow, Russia

Actively Recruiting

9

Research Site

Nizhny Novgorod, Russia

Not Yet Recruiting

10

Research Site

Obninsk, Russia

Actively Recruiting

11

Research Site

Omsk, Russia

Actively Recruiting

12

Research Site

Saint Petersburg, Russia

Not Yet Recruiting

13

Research Site

Saransk, Russia

Not Yet Recruiting

14

Research Site

Tomsk, Russia

Not Yet Recruiting

15

Research Site

Tyumen, Russia

Not Yet Recruiting

16

Research Site

Ufa, Russia

Not Yet Recruiting

17

Research Site

Yekaterinburg, Russia

Actively Recruiting

Loading map...

Research Team

A

AstraZeneca Clinical Study Information Center

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Treatment Approaches and Biomarkers PRevalence In de Novo MEtastatic Hormone-sensitive Prostate Cancer in Russian Federation | DecenTrialz